3.85
Sagimet Biosciences Inc stock is traded at $3.85, with a volume of 419.09K.
It is up +0.00% in the last 24 hours and down -6.10% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$3.85
Open:
$3.89
24h Volume:
419.09K
Relative Volume:
0.47
Market Cap:
$123.95M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-3.2462
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
+9.69%
1M Performance:
-6.10%
6M Performance:
+17.38%
1Y Performance:
-14.06%
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SGMT
Sagimet Biosciences Inc
|
3.85 | 123.95M | 0 | -29.25M | -22.80M | -1.186 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-06-24 | Initiated | Oppenheimer | Outperform |
Nov-12-24 | Initiated | UBS | Buy |
Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
May-02-24 | Initiated | H.C. Wainwright | Buy |
Mar-25-24 | Initiated | Leerink Partners | Outperform |
Aug-08-23 | Initiated | Goldman | Buy |
Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
Aug-08-23 | Initiated | Piper Sandler | Overweight |
Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Sagimet Biosciences (SGMT) Expected to Announce Earnings on Monday - Defense World
HC Wainwright Issues Positive Estimate for SGMT Earnings - Defense World
Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position - TipRanks
HC Wainwright Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom - TipRanks
Sagimet Biosciences Advances MASH Treatment with New Trials - TipRanks
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet’s FASN inhibitor cleared to enter clinic for acne - BioWorld Online
Sagimet Biosciences Inc. (SGMT) reports earnings - Quartz
Sagimet Biosciences Inc. SEC 10-K Report - TradingView
Sagimet's FDA Breakthrough Drug Enters Phase 3 Trials with $158M War Chest - StockTitan
Promising Developments in Sagimet Biosciences: IND Clearance for TVB-3567 and Ongoing Success of Denifanstat - TipRanks
Promising Pipeline and Positive Trial Data Support Buy Rating for Sagimet Biosciences - TipRanks
Sagimet Biosciences’ Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567 - TipRanks
Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials -March 11, 2025 at 10:46 am EDT - Marketscreener.com
Sagimet Biosciences receives FDA nod to begin testing its therapy for acne -March 11, 2025 at 09:38 am EDT - Marketscreener.com
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - SEC.gov
Sagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567 - TipRanks
Sagimet Biosciences Announces Clearance of IND for FASN - GlobeNewswire
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for ... - The Bakersfield Californian
FDA Clears Groundbreaking Acne Drug: Sagimet's New FASN Inhibitor Targets 50M Patient Market - StockTitan
Sagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT) - Seeking Alpha
Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? - Insider Monkey
10 Best Get Rich Quick Stocks To Invest In - Insider Monkey
Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.00 - Defense World
10 Hot Penny Stocks to Buy Now - Insider Monkey
Unveiling Hidden Gems: The Hot Penny Stock You Might Be Missing - Reporteros del Sur -
Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now - Insider Monkey
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sagimet Biosciences Announces Oral Presentation at the MASH - GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic ... - The Bakersfield Californian
Could This New MASH Drug Transform Liver Disease Treatment? Key Phase 2b Results Revealed - StockTitan
FY2024 Earnings Estimate for SGMT Issued By Leerink Partnrs - MarketBeat
Technical analysis of Sagimet Biosciences Inc (SGMT) stock chart patterns - US Post News
FY2024 Earnings Forecast for SGMT Issued By Leerink Partnrs - Defense World
Keeping an Eye on Sagimet Biosciences Inc (SGMT) After Insider Trading Activity - Knox Daily
Sagimet Biosciences Inc (NASDAQ:SGMT) Up 47.7% Since 52-Week Low; YTD Rose 1.56% – Here’s What You Need To Do – Marketing Sentinel - Marketing Sentinel
Equities Analysts Issue Forecasts for SGMT FY2029 Earnings - MarketBeat
Prepare Yourself for Liftoff: Sagimet Biosciences Inc (SGMT) - SETE News
Sagimet Biosciences Inc (SGMT)’s results reveal risk - US Post News
Analytical Overview: Sagimet Biosciences Inc (SGMT)’s Ratios Tell a Financial Story - The Dwinnex
US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks - Yahoo Finance
Buy Recommendation for Sagimet Biosciences: Denifanstat’s Unique Profile and Undervaluation Offer Compelling Investment Opportunity - TipRanks
What's Going On With Sagimet Biosciences Stock On Thursday? - MSN
JPMorgan Chase & Co. Boosts Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate - MSN
Barclays PLC Has $159,000 Stock Position in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):